- Devanand Sarkar, PhD
- Institute of Molecular Medicine, Virginia Commonwealth University, Richmond, USA.
Website | E-mail
Special Issue Introduction
The incidence of Hepatocellular Carcinoma (HCC) is increasing alarmingly, and it is the third most important cause of cancer-related deaths globally. HCC, diagnosed at early stages, is amenable to treatments and five-year survival rates of ~60 to 70% can be achieved in well-selected patients. However, most HCC cases are diagnosed at advanced stages with a dismal prognosis owing to underlying liver disease and inherent resistance of HCC to conventional chemo- and radiotherapy. This bleak scenario calls for better insights into the molecular and genomic classification of HCC which will guide the development and evaluation of novel, targeted therapeutic strategies. During the hepatocarcinogenesis process, a variety of genetic and epigenetic alterations accumulate. Several recent comprehensive studies have unraveled molecular diversity in human HCC patients facilitating molecular classifications based on transcriptomic, genetic, epigenetic and miRNA profiling. The purpose of the special issue is to create a comprehensive collection of the garnered knowledge under a single platform facilitating the in-depth understanding of the molecular pathogenesis of HCC. This endeavor will perk cross-thematic interest among researchers leading to the development of new modalities of combinatorial therapeutics. With this end in view, we invite authors to submit papers on the following potential topics:
1.Alteration of oncogenes and tumor suppressor genes in HCC
2.Classification of HCC based on transcriptome profile
3.Epigenetic changes in HCC: results from genome-wide methylation profiling
4.miRNAs regulating HCC
5.Long non-coding RNAs regulating HCC
6.Signaling pathways altered in HCC
7.Immunological characterization of HCC
8.Classification of HCC based on their metabolic profiles
9.Therapies based on molecular and genomic classification of HCC
Participants1. Lun-Xiu Qin Department of General Surgery, Huashan Hospital and Cancer Metastasis Institute, and Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
The list is arranged in no particular order and being updated.
Submission Deadline31 Oct 2020